Cancer Gene Therapy Market is projected to increase at a 10.1% CAGR from 2022 to 2032

[300+ Pages Report] As per Future Market Insights’ latest revised industry analysis, the global cancer gene therapy market is projected to expand at a 10.1% CAGR over the forecast period, with the market size reaching US$ 5.3 Bn in 2032.

Gene therapy is a field of medicine that aims to cure or greatly improve the treatment of diseases that have few or no treatment options. Advanced-stage cancer and hematological illnesses make up a large share of gene therapy candidates. In addition to this, gene therapy is frequently used to treat rare or inherited diseases.

While gene therapy research is still in its early stages, firms are increasingly investing in the technology. A handful of products have recently received approval outside of Canada or are in the final stages of clinical trials.

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14971

Gene therapy is currently extremely expensive. Multi-stakeholder discussions about pricing and reimbursement management for these goods are required. To provide accessibility and quality of care, specialized manufacturing facilities, care centers, and doctors skilled to undertake specific procedures for such therapies are required.

The growth in the cancer gene therapy market is reliant on increasing awareness about health, the growing incidence of cancer, and the latest advancements in cancer gene therapy.

“Rising awareness regarding cancer gene therapy across emerging economies, along with favorable healthcare reimbursement plans in various countries will create opportunities for growth in the market over the forecast period,” says an FMI analyst.

Key Players :

  • Merck KGaA
  • Novartis AG
  • AstraZeneca Plc.
  • BIOCAD
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Vicore Pharma AB
  • Amgen
  • Bristol-Myers Squibb
  • Cell Genesys Inc.
  • Adaptimmune Therapeutics plc.
  • Achieve Life Science Inc.
  • BioCanCell Ltd.
  • Genelux Corporation
  • Advantagene Inc.,
  • GenVec Inc.
  • GlaxoSmithKline PLC
  • Amgen Inc.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-question/rep-gb-14971

Key Takeaways:

  • Based on therapy, the oncolytic virotherapy segment accounted for about 3% of the total market share in 2021.
  • In terms of indication, sales in the breast cancer segment are forecast to grow at a CAGR of 7% in the forecast period.
  • By service provider, demand in the hospitals segment will grow at a 9.3% CAGR through 2032.
  • The U.S. will dominate the North America cancer gene therapy market over the forecast period.
  • China will emerge as a lucrative pocket, accounting for 32.3% of the East Asia cancer gene therapy market share over the assessment period.
  • Demand in Germany is expected to increase at a 11.9% CAGR over the assessment period.

Competition Landscape

Acquisitions, partnerships, geographical recognition, and product launches are the key strategies adopted by leading players to increase the consumer base. For instance:

  • In March 2022, Novartis and Carisma Therapeutics agreed to collaborate on the development of HER 2 targeted CAR-M cell therapy.
  • A2 Biotherapeutics and Merck announced a collaboration in December 2020 to develop allogeneic cell therapy for solid tumor cancers.

Want More Insights

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global cancer gene therapy market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the cancer gene therapy market segment based on therapy – (gene induced immunotherapy, oncolytic virotherapy, gene transfer, and others), by indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and prostate cancer), by service provider (hospitals, clinical research laboratory, and oncology institutes), across seven major regions.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-14971

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

By Therapy:

  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer
  • Others

By Indication:

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Prostate Cancer

By Service Provider:

  • Hospitals
  • Clinical Research Laboratory
  • Oncology institutes

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Joint Reconstruction Devices Market trade is projected at a 4.8% CAGR from 2022 to 2032

The global joint reconstruction devices market is worth US$ 26 Bn as of now and is expected to reach US$ 41.5 Bn by the year 2032 at a CAGR of 4.8% between 2022 and 2032.

Joint reconstruction comes across as a remarkable part of global orthopedic devices vertical. The conditions adversely affecting joints are inclusive of all kinds of arthritis, bone degenerative diseases, osteoporosis, and the other injuries. It needs to be noted that these ailments no longer pertain to aging population. Sedentary lifestyles are responsible for these ailments.

Joint reconstruction encloses a broad spectrum of treatments like physiotherapy, surgeries, and pain management. The very first type of therapy preferred is that of ‘physiotherapy’. Though it caters to primary care, surgical procedures do prove to be permanent course of cure. Minimally invasive surgeries are preferred as they provide benefits like convenience factor for surgeons and patients alike, lesser timespan of hospital stay, and shorter ‘turnaround’ time. Artificial implants dominate the joint reconstruction devices market as they offer simple installation. Arthroscopes enable outpatient surgeries as well. Advanced tools include image magnifiers and pre-operative planning.

Get Full PDF Sample Copy of Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14956

Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Joint Reconstruction Devices Market’ through its dedicated team of analysts and consultants. The bottom-up approach is bound to go a long way regarding the rapport with clientele. Also, micros and macros have been efficiently worked upon.

Key Takeaways from Joint Reconstruction Devices Market

  • North America holds more than 30% of the market share. This could be credited to the US housing a huge number of industry players.
  • Europe stands second on the similar grounds and the status quo is expected to remain unchanged even going forward.
  • The Asia-Pacific is expected to grow at the fastest rate in the joint reconstruction devices market. This could be attributed to FDI being approved by the governments of India and China. Japan is another country leading from the front.
  • With increase in the number of distribution partners, Mexico and Brazil are expected to dominate joint reconstruction devices market for LATAM.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14956

Competitive Devices

  • Smith + Nephew, in February 2022, did announce launching next generation handheld robotics platform called ‘CORI Surgical System’ at the commercial scale. It stands out from its counterparts with respect to compactness. Minimal set-up time along with portability implies that it could be moved from one theater to the other for optimizing patients’ flow via surgical units.
  • Zimmer Biomet Holdings, Inc., in December 2020, did announce that it had completed acquisition of A&E Medical Corporation and its entire portfolio comprising sternal closure devices. They included cable systems, sternal sutures, and rigid fixation.
  • DePuy Synthes, in March 2022, did acquire CUPTIMIZE Hip-Spine Analysis – a tool floated with the objective of better understanding and addressing effect of abnormal motion between pelvis and spine in certain patients who need THA (total hip arthroplasty). It improvises on surgical planning capabilities related to VELYS Hip Navigation (a solution from DePuy Synthes’ VELYS Digital Surgery platform for connected technologies).
  • LimaCorporate, in October 2022, did receive approval from the US FDA for a new-fangled shoulder platform emphasized on glenoid baseplate. Humeral stem is 3D-printed in its entirety. This dental implant system, using patented TT (Trabecular Titanium) technology, does aim to obtain robust primary fixation with successful growth of secondary bone.
  • Smith + nephew PLC, in September 2022, did launch OR3O dual mobility system for usage in revision and primary arthroplasty in Japan.

“With success with respect to rheumatoid arthritis and osteoarthritis, the global joint reconstruction devices market is bound to grow inadvertently in the near future”, says an analyst from Future Market Insights.

To receive extensive list of important regions, ask for TOC here @ https://www.futuremarketinsights.com/toc/rep-gb-14956

How does the Report reconstruct itself?

  • The research study is based on technology (joint reconstruction devices for joint replacement, joint reconstruction devices for osteotomy, joint reconstruction devices for arthroscopy, joint reconstruction devices for resurfacing, joint reconstruction devices for arthrodesis, and joint reconstruction devices for other technologies), and by type (knee joint reconstruction devices, hip joint reconstruction devices, shoulder joint reconstruction devices, ankle joint reconstruction devices, and other joint reconstruction devices).
  • With growing occurrences of orthopedic diseases coupled with increasing geriatric population, the global joint reconstruction devices market is expected to witness a noteworthy CAGR in the near future.

Key Segments Covered In The Joint Reconstruction Devices Industry Survey

Joint Reconstruction Devices Market by Technology:

  • Joint Reconstruction Devices for Joint Replacement
  • Joint Reconstruction Devices for Osteotomy
  • Joint Reconstruction Devices for Arthroscopy
  • Joint Reconstruction Devices for Resurfacing
  • Joint Reconstruction Devices for Arthrodesis
  • Joint Reconstruction Devices for Other Technologies

Joint Reconstruction Devices Market by Type:

  • Knee Joint Reconstruction Devices
  • Hip Joint Reconstruction Devices
  • Shoulder Joint Reconstruction Devices
  • Ankle Joint Reconstruction Devices
  • Other Joint Reconstruction Devices

Joint Reconstruction Devices Market by Region:

  • North America Joint Reconstruction Devices Market
  • Latin America Joint Reconstruction Devices Market
  • Europe Joint Reconstruction Devices Market
  • Asia Pacific Joint Reconstruction Devices Market
  • Middle East & Africa Joint Reconstruction Devices Market

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Digital Patient Monitoring Systems Market is projected to reach a valuation of US$ 470 Billion by 2032 | FMI

Future Market Insights, a market research and competitive intelligence provider, analyses that market demand for Digital Patient Monitoring Systems is expected to rise rapidly on the back of increasing demand for remote patient monitoring activities and increasing penetration in developing countries.

According to the study, the global Digital Patient Monitoring Systems market was valued at US$ 73.7 Bn in 2021, and it is expected to expand at a CAGR of 17.2% over the assessment period of 2022-2032 to reach 470 Bn by 2032. Owing to the significant growth in diabetic population which is expected to reach 701 Mn by 2045, diagnostics monitoring devices demand is projected to upscale continuously.

Attribute Details
Digital Patient Monitoring Systems Market Size (2021A) US$ 73.7 Bn
Market size value estimated in 2022E US$ 96.4 Bn
Market Forecast Value (2032F) US$ 470 Bn
Global Market Growth Rate (2022-2032) 17.2% CAGR
Countries with high Market Share
  • USA
  • China
  • India
US Market Growth Rate 15.5% CAGR
Key Companies Profiled
  • Abbott Laboratories
  • Hill-Rom Holdings, Inc.
  • Drägerwerk AG & Co.
  •  Edwards Lifesciences Corporation
  • OMRON
  • Mosimo Corporation

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-14951

The market for Digital Patient Monitoring Systems is dominated by companies such as Abbott, Athenahealth, Biotronik SE & Co. KG, FitBit and MedTronic. North America leads the market for dynamic patient monitoring equipment as a result of its substantial R&D capital, the incidence of infectious diseases, safety concerns, and technological advancements in these products. The ASEAN region is experiencing a significantly growing market potential in the foreseeable future due to increasing smartphone-install base.

Digital Patient Monitoring Systems are used extensively for diagnostic purposes.  Diagnostic Monitoring Devices segment of Digital Patient Monitoring Systems is projected to increase at a CAGR of around 14.8% over the decade (2022-32). The rising prevalence of diseases such as diabetes, obesity, cancer, and others, as well as the growing geriatric population, are propelling the segment’s growth.

Key Takeaways from Market Study

  • The Digital Patient Monitoring Systems market is anticipated to add 11.7X value by 2032.
  • The market is expected to expand at a considerable growth rate of 17.2% and be valued at US$ 470 Bn by 2032.
  • Abbott, Medtronic and Athenahealth are the top giants in Digital Patient Monitoring Systems manufacturing.
  • Based on product type, diagnostic devices accounted for around 62% of the global market share in 2021.
  • The MedTech behemoth, Medtronic has joined forces with Rockley Photonics to develop a new wearable type digital monitoring device in March 2022. Launching innovative Digital Patient Monitoring Systems is expected to be a future trend.

Ask Analyst for Report Customization and Explore TOC & List of Figures @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-14951

“The spread of COVID-19 pandemic has prompted remote patient monitoring activities, as well as the use of mHealth apps and telehealth devices, while also catalysing demand for digital medicine. This has resulted in increased demand for digital patient monitoring equipment and created the market for Digital Patient Monitoring Systems has enormous growth potential.” says a Future Market Insights analyst.

More Valuable Insights Available

Future Market Insights , in its new offering, presents an unbiased analysis of the global Digital Patient Monitoring Systems market, presenting historical market data (2016-2021) and forecast statistics for the period of 2022-2032.The study reveals essential insights by Product Type (Diagnostic and Therapeutic Devices), by Type ( Wireless Sensor Technology, mHealth, Telehealth, Wearable Devices, and Remote Patient Monitoring) and across key regions (North America, Latin America, Europe, East Asia, South Asia & Oceania, and the Middle East & Africa).

Grow your profit margin with Future Market Insights – Buy the report@ https://www.futuremarketinsights.com/checkout/14951

Key Segments Covered in Digital Patient Monitoring Systems Industry Survey

Digital Patient Monitoring Systems Market by Product Type:

  • Diagnostic Monitoring Devices
    • Vital Sign Monitors
    • Sleep Monitors
    • Fetal Monitors
    • Neuromonitors
    • Other Diagnostic Monitoring
  • Therapeutic Monitoring Devices
    • Insulin Monitors
    • Respiratory Monitors
    • Other Therapeutic Monitors

Digital Patient Monitoring Systems Market by Type:

  • Wireless Sensor Technology
  • mHealth
  • Telehealth
  • Wearable Devices
  • Remote Patient Monitoring

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Canned Food Packaging Market Attain a Valuation of US$ 44,568.5 Million By 2032: Innovations and Opportunities in the Global Industry

The global canned food packaging market is anticipated to reach a value pool of US$ 27,887.9 Million in 2022, rising at a CAGR of 4.8% to attain a valuation of US$ 44,568.5 Million between 2022 and 2032. Growth is being fueled by technological development and increased consumer demand for packaged foods and beverages. Between 2016 and 2021, the market for the packaging of canned foods expanded at a CAGR of 3.3%. Food that has been processed or canned provides an excellent supply of nutrients, shields the food from the elements, and is hygienic. The most popular kind of canned food is packaged in metal because it is simple to use, transport, and eat.

Canned food packaging involves the use of metal cans, glass jars, and plastic containers to preserve food. The packaging helps in preserving the flavor, texture, and nutritional value of the food for an extended period, making it convenient for consumers to store and use. The canned food packaging market is segmented based on material, product, distribution channel, and region.

Avail Free PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-4104

One of the main drivers of the canned food packaging market is the increasing demand for convenience food, which has led to an increase in the consumption of canned food products. Additionally, the longer shelf life of canned food products compared to fresh food products has also contributed to the growth of this market.

Canned food packaging prevents the product from getting spoilt by protecting it from environmental factors and external stimuli like pollution and heat. This packaging offers greater security and extends the shelf life of the product. Canned food packaging is an affordable method of preserving perishable food items with little to no change in the flavor. Consequently, there is high demand for this packaging from the advancing horticulture and seafood processing sectors. Canned food products are also easy to consume and transport. In addition to this, easy access and increasing availability of canned goods fosters an environment of growth for the canned food packaging market during the period under observation.

“Large scale acceptance of canned food products due to protection against all kind of microbial contamination is likely to boost the sales of canned food packaging over the forecast period,” says an FMI analyst.

The recyclable and reusable property of the cans is another growth driver of the market. Again, canned food items are rising in popularity due to their nutritional value and hygiene quality. Moreover, factors like swiftly changing lifestyles, rising disposable income, affordable pricing of canned food products as well as the availability of a wide range of choices drives the canned food packaging market. Besides, incorporation of technological advancements in the packaging process have led to the generation of new techniques for packing canned food. This, too, bodes well for the canned food packaging market.

Key Takeaways:

  • Heightened demand for ready-to-eat and seasonal food products fosters market growth for canned food packaging
  • High manufacturing cost and a time consuming production process may impede the market growth.
  • In 2022, canned food packaging market in North America is anticipated to account for 29% of the market share.
  • Elevated demand for packed food drives the market in Europe over the assessment period.
  • By type of food, the seafood segment is expected to dominate the market.
  • Based on raw material, aluminum is expected to account for a high demand, exhibiting a CAGR of 4.5%

Expand operations in the future – To get requisite details, ask for a custom report. https://www.futuremarketinsights.com/customization-available/rep-gb-4104

Competitive Landscape 

Ball Corporation, Del Monte Foods, Inc., Crown Holdings, Amcor Limited, Anchor Glass Container Corporation, Ardagh Group, Greif Incorporated, Toyo Seiken, Huber Packaging and Siligan Containers among others are some of the major players in the canned food packaging market that are profiled in the full version of the report.

In an extremely competitive market, major players are keen on expanding operations and entering new markets. These businesses are also engaged in product development so as to maintain a competitive advantage.

Challenges in Canned Food Packaging Market

The canned food packaging market faces several challenges, such as the increasing demand for fresh food and the negative perception of canned food.

  • Fresh Food Trend- The increasing trend for fresh food and the perception that canned food is less healthy and less tasty than fresh food poses a challenge for the canned food packaging market. Manufacturers are developing packaging designs and materials that promote the nutritional value and taste of canned food.
  • Negative Perception- The negative perception of canned food, such as the use of preservatives and the concern for BPA (bisphenol A) in metal cans, poses a challenge for the canned food packaging market. Manufacturers are developing packaging materials that are BPA-free and promoting the use of natural preservatives.

Opportunities in Canned Food Packaging Market 

  • Private Label Brands- Private label brands are gaining popularity in the canned food packaging market due to the lower cost and higher profit margin for retailers. Manufacturers are developing packaging designs and materials that can be easily customized for private label brands.
  • E-commerce Channels- E-commerce channels are gaining popularity in the canned food packaging market due to the increasing demand for online shopping and the convenience of home delivery. Manufacturers are developing packaging designs and materials that are suitable for e-commerce channels, such as lightweight and durable packaging.
  • Emerging Markets- Emerging markets, such as Asia-Pacific and Latin America, provide significant opportunities for the canned food packaging market due to the increasing population, urbanization, and rising disposable income. Manufacturers are developing packaging designs and materials that are suitable for these markets, such as smaller packaging sizes and localized designs.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-4104

Key Segments Profiled in the Canned Food Packaging Industry Survey

Canned Food Packaging Market by Type of Food:

  • Canned Fish and Seafood
  • Canned Vegetables
  • Canned Meat Products
  • Canned Fruits
  • Canned Ready Meals
  • Milk and Sauces
  • Beans and Legumes
  • Other Canned Food Products

Canned Food Packaging Market by Distribution Channel:

  • Canned Food Packaging for Supermarkets and Hypermarkets
  • Canned Food Packaging for Independent Retailers
  • Canned Food Packaging for Convenience Stores
  • Canned Food Packaging for Specialist Retailers
  • Canned Food Packaging for Other Distribution Channels

Canned Food Packaging Market by Raw Material:

  • Aluminium Canned Food Packaging
  • Steel Canned Food Packaging
  • Tinplate Canned Food Packaging
  • Glass Canned Food Packaging
  • Plastic Canned Food Packaging

Canned Food Packaging Market by Types of Can:

  • 3-piece Welded Food Packaging Cans
  • 2-piece Food Packaging Cans
  • D&I Food Packaging Cans
  • DRD Food Packaging Cans
  • Drawn Wall-Ironed Food Packaging Cans
  • Single Drawn Food Packaging Cans
  • Open Top Sanitary Food Packaging Cans

Canned Food Packaging Market by Preservation Technique:

  • Pressurized Food Packaging Cans
  • Vacuum Food Packaging Cans

Canned Food Packaging Market by Region:

  • North America Canned Food Packaging Market
  • Latin America Canned Food Packaging Market
  • Europe Canned Food Packaging Market
  • Asia Pacific Canned Food Packaging Market
  • Middle East & Africa Canned Food Packaging Market

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Buy Now to gain access to detailed information about each segment. https://www.futuremarketinsights.com/checkout/4104

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com

Equine Veterinary Therapeutics Market is predicated to reach US$ 2515.75 million in 2032

321 pages of text The FMI report projects that between 2022 and 2032, the global market for equine veterinary therapeutics will expand at a CAGR of 6.8%. It is predicted to increase from US$ 1307.64 million in 2022 to US$ 2515.75 million in 2032.

Equine veterinary therapeutics is the branch of equine healthcare that deals with the prevention and treatment of several diseases. Equine veterinary therapeutics includes drugs that is used for the treatment of equine diseases, vaccines that used for the prevention of several disease and prevention of equine from various pathological conditions and additives that is used for the overall maintenance of heath and providing with sufficient minerals for a healthy life.

Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and development of the Equine Veterinary Therapeutics Market. The study features insights on the current growth dynamics and the major revenue reforms prevailing in the market as along with the key takeaways over the forecast.

The team of analysts at Future Market Insights are focussing on research and market study to produce different Equine Veterinary Therapeutics Market forecasts and predictions at both national and international levels. They have considered several leads of information pertaining to the industry like market figures and merger estimations to assess and produce reliable and informative insights on the Equine Veterinary Therapeutics Market.

To remain ‘ahead’ of your competitors, Ask a Question >> https://www.futuremarketinsights.com/ask-question/rep-gb-2500

Key Players

The writer will create content on the general strategies of market players. And then will write the key players in the market are: Merck animal heath, Affymetrix, Elanco animal heath,Zoetis (Pfizer Animal Health), Equine Health U.K.and others

Segmentation

The report provides insights on the important highlights and current trends prevailing in the market. This helps the readers to gain a deeper understanding and form an unbiased opinion on the market. Numerous segmentations have been provided for this market based on:

Global equine Veterinary Therapeutics Market, by Product Type

  • Drugs
  • Anti- Inflammatory
  • Anti – Infective
  • Parasiticides
  • Vaccines
  • Recombinant vaccines
  • Inactivated Vaccines
  • Live attenuated vaccines
  • Feed additives
  • Vitamins
  • Antibiotics
  • Amino acids
  • Enzymes
  • Others

Global equine Veterinary Therapeutics Market, by route of administration

  • Oral
  • Parental
  • Topical

Global equine Veterinary Therapeutics Market, by Distribution Channel

  • Veterinary Hospital
  • Veterinary Clinics
  • Pharmacies and drug stores
  • E-commerce
  • Other

Product Segmentation

The investigation offers a top to bottom evaluation of different clients’ journeys pertinent to the market and its segments. The study endeavours to assess the current and future development possibilities, undiscovered roads, factors that shapes their income potential in the global market by breaking it into di such as its types, applications, and region-wise assessment.

Get Access to Research Methodology Prepared by Experts >> https://www.futuremarketinsights.com/askus/rep-gb-2500

By Regional Analysis Covered

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

Full in-depth analysis of the parent market

The analysts at FMI are dedicated to provide insights after extensive research and study. The study also includes estimations, projections and evaluation of the market dynamics.

Important changes in market dynamics

The report has been created after detailed and exhaustive studies by the analysts at FMI taking several factors into consideration like monetary, ecological, social, mechanical, and political status of a particular demography. They study the key data to assess the revenue and production of manufacturers across various regions. The report also covers an in-depth analysis of the key changes in market dynamics in the recent past and the near future.

Segmentation details of the market

  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional markets

Queries Solved

  • What is the size of the overall Equine Veterinary Therapeutics Market in the Healthcare Industry and its segments?
  • What are the key segments and sub-segments in the market?
  • What are the key drivers, restraints, opportunities, and challenges of the Equine Veterinary Therapeutics Market in the Healthcare Industry, and how they are expected to impact the market?
  • What are the attractive investment opportunities within the Equine Veterinary Therapeutics Market in the Healthcare Industry?
  • What is the Equine Veterinary Therapeutics Market in the Healthcare Industry size at the regional and country-level?
  • What are the key market players focusing on?
  • What are the strategies for growth adopted by the key players in Equine Veterinary Therapeutics Market in the Healthcare Industry?
  • What are the recent trends in Equine Veterinary Therapeutics Market in the Healthcare Industry? (M&A, partnerships, new product developments, expansions)?
  • What are the challenges to the Equine Veterinary Therapeutics Market in the growth of the Healthcare Industry?
  • What are the key market trends impacting the growth of the Equine Veterinary Therapeutics Market in the Healthcare Industry?

To receive extensive list of important regions, ask for TOC here >> https://www.futuremarketinsights.com/toc/rep-gb-2500

Table of Content

  • Executive Summary
  • Market Overview
  • Key Success Factors
  • Global Equine Veterinary Therapeutics Market – Pricing Analysis
  • Market Background

Reasons to Buy the report

  • We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
  • Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
  • The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Mucosal Atomization Devices Market is projected to register growth in Europe at a rate of 7.4% CAGR from 2022 to 2029

According to a recent market study by Future Market Insights (FMI), the global market for mucosal atomization devices was valued at US$ 460.4 million in 2021 and is projected to grow to US$ 837.7 million by 2029.

A new market research report by Future Market Insights on the mucosal atomization devices market includes global industry analysis 2014–2021 and opportunity assessment 2022–2029. Mucosal atomization devices market was valued at ~US$ 490.2 Mn in 2022, and is expected to increase at a robust CAGR of ~8% during the forecast period. The demand growth is majorly driven by superior efficiency and painless drug delivery nature of mucosal automization devices, according to the report.

The market is still young, and FMI’s analysis expects a considerable increase in penetration rate over the course of coming years, in line with the thriving trends, such as non-invasive treatments and needleless drug delivery systems.

Developed regional markets are expected to hold prominent market share in terms of value. The market in Asia Pacific is also expected to grow at a significant rate. North America is expected to account for leading revenue shares in the mucosal atomization devices over the foreseeable future, predominantly attributing to the technological advancements in the field of healthcare. The rate of adoption of drug delivery devices has been envisaged to remain high in Europe, which is driving the region’s mucosal atomization devices market. On the other side, the market in Asia Pacific is expected to grow at a significant growth rate as a result of the increasing frequency of new and efficient medical device launches.

Find a comprehensive report summary that describes the market size and forecast along with the research methodology. The Sample report is available in PDF format @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7101

Mucosal Atomization Devices Market Segmentation

The global market of mucosal atomization devices has been segmented on the basis of product type, technology, end user and regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa

By product type, nasal atomization devices are expected to hold prominent value shares of the global mucosal atomization devices market. Nasal passage is the most common route of administration, hence, nasal atomization devices are expected to show significant growth in the mucosal atomization devices market.

On the basis of technology, gas propelled atomization devices are expected to hold a large revenue share in the mucosal atomization devices market. Most of the key players operating in mucosal atomization devices market, are manufacturing gas propelled mucosal atomization devices.

On the basis of end user, hospitals hold a significant share in the mucosal atomization devices market. The number of hospitals are increasing, especially in the developed regions, which is expected to increase the demand for mucosal atomization devices, increasing the growth of the mucosal atomization devices market.

Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-7101

Mucosal Atomization Devices Market: Vendor Insights

The report highlights some of the prominent market players, who have established themselves as leaders in the global mucosal atomization devices market. Some of the examples of key players in the global mucosal atomization devices market are Teleflex Incorporated, DeVilbiss Healthcare LLC, Cook Medical Incorporated, and Medica Holdings, LLC, Kurve Technology. There are only few key players in the mucosal atomization devices market.

Key players are majorly focusing on the development of new and technologically advanced mucosal atomization devices. Key players are also involved in acquisitions and collaborations, which can increase the growth of the mucosal atomization devices market.

Mucosal Atomization Devices Market by Category

By Product Type:    

  • Nasal Atomization Devices
  • Fiber Optic Atomization Devices
  • Laryngo Tracheal Atomization Devices
  • Bottle Atomizers

Buy Now to Gain Access to Detailed Information About Each Segment and Identify Key Trends, Drivers, and Challenges in the Market@ https://www.futuremarketinsights.com/checkout/7101

By Technology:

  • Gas Propelled Atomization Devices
  • Electrical Atomization Devices

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Clinics

Key Questions Answered in the Report

  • How much is the Mucosal Atomization Devices market currently worth?
  • What was last 5 year market CAGR?
  • What will be demand outlook/sales forecast of Mucosal Atomization Devices market?
  • Which is the most lucrative market for Mucosal Atomization Devices market?
  • At what percentage Mucosal Atomization Devices market is expected to register growth in Europe?
  • How likely is the Mucosal Atomization Devices market to grow in China?
  • What are key trends driving sales of Mucosal Atomization Devices?
  • What are the key market statistics in South Korea and Japan?
  • What are the top 5 countries driving demand for Mucosal Atomization Devices market?
  • Which are leading companies of Mucosal Atomization Devices market?

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Pharmacovigilance Market size is projected to be valued at US$ 24.32 billion by 2032 | Get Insights FMI

[315 Pages Report] ESOMAR-certified company Future Market Insights (FMI) has published a report on the global pharmacovigilance market for the forecast period 2021-2031. According to the report, the market is poised to reach new heights, as pharmaceutical companies scramble to introduce new drug candidates for multiple ailments, which will result in an increase in clinical trials.

As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.

Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-1107

Key Takeaways from FMI’s Pharmacovigilance Market Study

  • By phase of drug development, stage IV clinical trials pharmacovigilance solutions account for over 3 out of 4 applications
  • Based on method type, targeted spontaneous reporting to make maximum use of pharmacovigilance solutions
  • By service provider type, contract outsourcing to generate almost two out of five pharmacovigilance solutions uptake
  • US experiencing robust pharmacovigilance solutions providers presence amid prevalence of good PV practices
  • Forthcoming clinical trials for numerous drug candidates through 2021 to widen UK’s growth prospects
  • India to emerge as an emerging pharmacovigilance hub amid growing trends of medical operations outsourcing
  • China to experience growth on the back of recent amendments to render pharmacovigilance implementation stronger

“Rising prevalence of chronic and infectious ailments is prompting multiple pharmaceutical giants to initiate widespread clinical trials for potential drug molecules, generating a highly competitive environment and generating major revenue pools,” says the FMI analyst.

Competitive Landscape

Prominent pharmacovigilance solutions providers are relying on collaborating with prominent biopharmaceutical and pharmaceutical companies to offer their digital solutions to facilitate effective patient care solutions. Also, offering advanced solutions is another prominent strategy. Some prominent faces include F. Hoffmann- La Roche, GlaxoSmithKline Plc., Covance Inc., ICON Plc. and iGATE Corporation among others.

Covance Inc. is a prominent pharmacovigilance solutions providing, offering end-to-end PV services spanning clinical and post-marketing phases from medical contract centers to ICSRs to medical reviews to electronic regulatory submissions. The system helps track weekly, daily and monthly metrics for quality, productivity and efficiency.

In April 2020, ICON Plc. initiated efforts to enhance pharmacovigilance practices, considering the onset of COVID-19. A webinar conducted on this issue by the company called for key pharmaceutical companies to automate their workflows by installing proactive and dedicated intelligence processes, forging detailed business and continuity plans and a virtually globally distributed footprint.

Talk with our analyst and get the complete information of report now@ https://www.futuremarketinsights.com/ask-question/rep-gb-1107

More Insights on the Global Pharmacovigilance MarketIn its latest report, FMI offers an unbiased analysis of the global pharmacovigilance market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of phase of drug development (preclinical studies, phase I, phase II, phase III and phase IV), type of methods (spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining), service type provider (in-house pharmacovigilance and contract outsourcing) and region (North America, Latin America, Europe, Asia-Pacific and Middle East & Africa).

Pharmacovigilance Market – Key Segments CoveredPhase of Drug Development

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Type of Methods

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Service Type Provider

  • In-house Pharmacovigilance
  • Contract Outsourcing

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-1107

Geography

  • North America (US and Canada)
  • Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe)
  • Asia-Pacific (China, India, ASEAN, Japan and Rest of APAC)
  • Latin America (Brazil, Mexico and Rest of LATAM)
  • Middle East & Africa (GCC, South Africa and Rest of MEA)

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Rosai-Dorfman Disease (RDD) Therapeutics Market value of US$ 431 Million in 2023 | Exclusive Report by FMI

During the forecast period 2023 to 2033, the Rosai-Dorfman Disease (RDD) Therapeutics market is expected to grow at a value of 6.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Rosai-Dorfman Disease (RDD) Therapeutics is expected to rise up to a market valuation of US$ 839.95 Million. The global RDD therapeutics market is expected to experience significant growth in the coming years, driven by advances in diagnostic technologies and the development of novel therapies.

RDD is typically diagnosed through a combination of clinical examination, imaging studies, and tissue biopsy. Once a diagnosis is confirmed, treatment options include watchful waiting, corticosteroid therapy, radiation therapy, and surgery. However, current treatments are often ineffective and can cause significant side effects, highlighting the need for more effective and targeted therapeutics.

Key companies are exploring the use of immune checkpoint inhibitors, such as PD-1 inhibitors, to treat RDD. These therapies work by blocking the immune checkpoints that cancer cells use to evade detection and destruction by the immune system. While still in early stages of development, these therapies hold great promise for the treatment of RDD.

Find a comprehensive report summary that describes the market size and forecast along with the research methodology. The Sample report is available in PDF format @  https://www.futuremarketinsights.com/reports/sample/rep-gb-16716

Key Takeaways from the Market Study

  • The Rosai-Dorfman Disease (RDD) Therapeutics market is expected to grow at a value of 6.9% CAGR in the forecast period 2023-2033
  • By distribution channel, hospital pharmacies are expected to possess 46% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.
  • North America is expected to possess 40% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.
  • Asia Pacific is expected to possess 35% market share for Rosai-Dorfman Disease (RDD) Therapeutics market in 2023.

“Development of targeted therapeutics and personalized medicine is expected to provide significant growth opportunities in the coming years.” states an FMI analyst

Competitive Landscape

Key players in the Rosai-Dorfman Disease (RDD) Therapeutics market are Teva Pharmaceuticals Ltd., Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd, Advanz Pharmaceticals, Novartis AG, Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd, Viatris Inc., Pfizer Inc.

  • Teva Pharmaceuticals Ltd, a key player in the Rosai-Dorfman Disease (RDD) Therapeutics market is focusing on investing in research and development to innovate medication for treating the ailment.
  • Zydus Pharmaceuticals, Inc, another key player in the Rosai-Dorfman Disease (RDD) Therapeutics market is focusing on integrating technology to understand the nature of the ailment and innovate medication for early-stage treatment.

Talk with our analyst and get the complete information of report now@  https://www.futuremarketinsights.com/ask-question/rep-gb-16716

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Rosai-Dorfman Disease (RDD) Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of drug class (MEK-inhibitors, Immunosuppressants and modulators, Chemotherapy), Treatment (PET Scan, CT scan, MRI, Ultrasounds, Blood Tests) End User (Hospitals and Clinical Laboratories) Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Key Segments Profiled in the Rosai-Dorfman Disease (RDD) Therapeutics Industry Survey

Drug Class:

  • MEK-inhibitors
    • Cobimetinib
    • Trametinib
    • Binimetinib
  • Immunosuppressants and modulators
    • Mercaptopurine
    • Azathioprine
    • Lenalidomide
    • Thalidomide
  • Chemotherapy
    • Cladribine
    • Cytarabine
    • Vinblastine
    • Hydroxyurea
    • Methotrexate

Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/request-discount/rep-gb-16716

Treatment:

  • PET Scan
  • CT scan
  • MRI
  • Ultrasounds
  • Blood Tests

End User:

  • Hospitals
  • Clinical Laboratories

Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Drug Designing Tools Market rising at a CAGR of 8.7% from 2022 to 2028

[220 Pages Report] The global drug designing tools market is expected to grow from US$ 1,777.3 Mn in 2021 to US$ 5,150.1 Mn by 2028, expanding at a CAGR of 8.7% in terms of revenue during the forecast period (2022-2028). In a new report by Future Market Insights, the global drug designing tools market is tracked in terms of value and is calibrated to obtain the market revenue estimates. The adoption of advanced technologies in drug designing tools and increasing requirement of time- and cost-effective tools are boosting growth of the drug designing tools market. However, infrastructure compatibility is a major problem faced by most organizations and is likely to challenge revenue growth of the global drug designing tools market.

To understand and assess the demand and opportunities in the drug designing tools market, the report is categorically split into four major sections that focus on market analysis by solutions, by application, by end user, and by region.

Get Full PDF Sample Copy of Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3806

The section – market analysis by solutions comprehensively analyses the market on the basis of multi databases, virtual screening tools, structure designing/building tools, predictive analytics, model building tools, and other solutions in terms of value for the period 2022-2028. In 2022, the multi databases segment dominated the drug designing tools market, followed by the virtual screening tools segment. The predictive analytics segment is projected to expand at the fastest CAGR of 13.22% over the forecast period in the drug designing tools market in terms of revenue, followed by the virtual screening tools segment.

The section – market analysis by application, analyses the various applications that use drug designing tools, and the data is provided in terms of value for 2022-2028. The binding site prediction segment is expected to expand at a significant CAGR of 12.75% in terms of value during the forecast period. In terms of market share, the docking segment accounted for a major percentage of the revenue share of the overall market in 2021, and is expected to dominate the drug designing tools market throughout the forecast years, followed by the target prediction segment.

The section – market analysis by end user, analyses various users that use tools in research and development, and the data is provided in terms of value for 2022-2028. The contract research organisations segment is expected to expand at a significant CAGR of 11.99% in terms of value during the forecast period. In terms of market share, the pharmaceutical companies segment accounted for a major percentage of the revenue share of the overall market in 2021, and is expected to dominate the drug designing tools market throughout the forecast years, followed by the biotechnology companies segment.

The section – market analysis by region includes an in-depth country-level analysis of the key regions in the world, namely, North America, Latin America, Western Europe, Eastern Europe, SEA & Others of APAC, China, Japan, and Middle East & Africa by product type, end user, and countries; and provides market data in terms of value for the forecast period 2022-2028. In 2022, the market in North America dominated the overall global drug designing tools market, followed by the market in Western Europe.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3806

Key Segments of Drug Designing Tools Industry Analysis

Drug Designing Tools Market by Solution:

  • Multi Databases
  • Virtual Screening Tools
  • Structure Designing/ Building Tools
  • Predictive Analytics
  • Model Building Tools
  • Others

Drug Designing Tools Market by Application:

  • Chemical Screening
  • Molecular Modeling/ Homology Modeling
  • Target Prediction
  • Binding Site Prediction
  • Docking
  • Energy Minimization
  • Others

Drug Designing Tools Market by End User:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Others

Drug Designing Tools Market by Region:

  • North America Drug Designing Tools Market
  • Latin America Drug Designing Tools Market
  • Europe Drug Designing Tools Market
  • East Asia Drug Designing Tools Market
  • South Asia & Pacific Drug Designing Tools Market
  • Middle East & Africa (MEA) Drug Designing Tools Market

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Meningococcal Vaccines Market is projected to reach US$ 7.7 Billion by the end of 2032 | FMI Study

(Report of 312 Pages) Over the forecast period, the market for meningococcal vaccines is anticipated to grow at a CAGR of 8.6%, reaching US$ 3.4 Bn in 2022. According to Future Market Insights (FMI), the conjugate vaccines segment held a 62.6% revenue share of the market in 2021.

The global meningococcal vaccines market is expected to grow at an 8.6% CAGR during the forecast period, reaching US$ 3.4 billion in 2022. According to Future Market Insights (FMI), the conjugate vaccines segment will have a 62.6% revenue share in 2021.

Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives.

The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need.

The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not for profits like the Global Alliance for Vaccines and Immunization (GAVI).

Get Full PDF Sample Copy of Latest Reports @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1252

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is Brazil.

In 2010, Ezequiel Dias Foundation, Brazil formed a strategic alliance with Novartis Vaccines & Diagnostics for the sustainable supply of Menjugate MenC vaccines for Brazil’s National Immunization Program. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time boost growth of the meningococcal vaccines market.

Key Companies Profiled:

  • Sanofi Pasteur Inc.
  • GlaxoSmithKline Plc
  • Wyeth Pharmaceuticals
  • Bio-Manguinhos
  • Bio-Med Pvt. Limited
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Ltd.
  • Pfizer INC
  • Serum Institute of India Pvt. Ltd
  • Walvax Biotechnology Co., Ltd.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1252

Factors Leading to Worldwide Adoption of Meningococcal Vaccination Programmes

The global meningococcal vaccines market is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines bolstered by immunisation alliances and mass vaccination campaigns among others.

Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating the speedy introduction of vaccines in some of the economically challenged countries of the Middle East and Africa region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the U.S and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further boosting the growth trajectory of the global market for meningococcal vaccines.

GlaxoSmithKline to Lead the Global Meningococcal Vaccines Market with About 50% Market Share Recorded in 2017

The global meningococcal vaccines market is highly consolidated, with GlaxoSmithKline and Sanofi together holding about 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017.

Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies.

Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets; while GlaxoSmithKline has 5 active pipeline programmes for meningococcal vaccines, all of which are in the phase II clinical stage. Addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1252

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Key Market Segments Covered in Meningococcal Vaccines Industry Research

By Product:

  • Polysaccharide
  • Conjugate

By Age Group:

  • Infants
  • Children
  • Adolescents & young Adults
  • Adults

By Distribution Channel:

  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others (hospital pharmacy, private market etc.)

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs